TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2387803

Group type: EXPERIMENTAL
Intervention: Reminder telephone call
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orientation letter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both a telephone prompt and an orientation letter
Number of subjects: 0

Group type: COMPARATOR
Intervention: No contact
Number of subjects: 0
Study: 6169671

Group type: EXPERIMENTAL
Intervention: Topical application of human leukocyte interferon (HLI) ointment (4,000 units/g) for 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical application of human leukocyte interferon (HLI) in the form of powder and solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combined local and general therapy
Number of subjects: 18
Study: 31725504

Group type: EXPERIMENTAL
Intervention: Relative position of contour height of zygomatic bone (male)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Relative prominence of zygomatic bone (male)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Relative prominence of zygomatic arch (male)
Number of subjects: 108
Study: 31841496

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: RFA followed by intralesional 5-fluorouracil (5-FU) injections
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: RFA
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of RFA with verapamil and 5-FU
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: RFA as monotherapy or in combination with chemotherapy
Number of subjects: 17
Study: 29441450

Group type: EXPERIMENTAL
Intervention: Active photobiomodulation plus physiotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo photobiomodulation plus physiotherapy
Number of subjects: 25
Study: 27616885

Group type: EXPERIMENTAL
Intervention: Theracurmin(®) 90 mg twice a day for 24 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 24602923

Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg, once daily) and peg-interferon α-2a and ribavirin (PR)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo and peg-interferon α-2a and ribavirin (PR)
Number of subjects: 393
Study: 22341737

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1391
Study: 20455991

Group type: EXPERIMENTAL
Intervention: ICD treatment
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: New York Heart Association class > II
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: QRS >120 ms
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Heart rate ≥ 80
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Prerenal azotemia (BUN:creatinine > 20)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Occurrence of 1 HF event
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Occurrence of 2 HF events
Number of subjects: 1218
Study: 17061151

Group type: EXPERIMENTAL
Intervention: Postoperative multidisciplinary intervention program
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Postoperative multidisciplinary intervention program (specifically for patients with dementia)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (standard care for patients with dementia)
Number of subjects: 199
Study: 16267706

Group type: EXPERIMENTAL
Intervention: Postoperative radio-chemotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: No postoperative therapy
Number of subjects: 32
Study: 11867410

Group type: EXPERIMENTAL
Intervention: IV tropisetron 5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: IV dexamethasone 5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study: 10395859

Group type: EXPERIMENTAL
Intervention: 4% gel (Conceptrol)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3.5% gel (Advantage-24)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 28% vaginal contraceptive film
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All N-9 preparations
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 48
Study: 7759462

Group type: EXPERIMENTAL
Intervention: Midaglizole (MID) 200 mg pre- and post-treatment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Midaglizole (MID) 200 mg pretreatment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Midaglizole (MID) 200 mg posttreatment
Number of subjects: 4

Group type: COMPARATOR
Intervention: Allergen alone (control phase)
Number of subjects: 4
Study: 31975265

Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinical pathway protocol implemented after 2012
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics dosed within 1 hour
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Redosing of antibiotics
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Betadine irrigation
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Vancomycin administration
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Compliant antibiotics dosing
Number of subjects: 247
Study: 28647549

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 728

Group type: COMPARATOR
Intervention: Standard procedures (Control)
Number of subjects: 728
Study: 25788030

Group type: EXPERIMENTAL
Intervention: Narrow gastric tube (NGT) reconstruction
Number of subjects: 104

Group type: COMPARATOR
Intervention: Whole-stomach (WS) reconstruction
Number of subjects: 104
Study: 23281646

Group type: COMPARATOR
Intervention: Implementation of quality indicators based on evidence-based guidelines for CS in 12 hospitals (6 intervention hospitals).
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Quality indicators measuring adherence to guideline recommendations on CS.
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Interviews with healthcare professionals and patients.
Number of subjects: 2000
Study: 21166610

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 548

Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) - olanzapine, quetiapine, risperidone
Number of subjects: 548
Study: 18325135

Group type: EXPERIMENTAL
Intervention: diet C (increased consumption of cereals, especially breakfast cereals)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: diet C
Number of subjects: 57

Group type: COMPARATOR
Intervention: diet V (increased consumption of vegetables)
Number of subjects: 57

Group type: COMPARATOR
Intervention: diet V
Number of subjects: 57
Study: 17717913

Group type: EXPERIMENTAL
Intervention: Total panax notoginseng saponins (PNS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine therapy with diclofenac sodium, Leflunomide and prednisone
Number of subjects: 84
Study: 14996523

Group type: EXPERIMENTAL
Intervention: Budesonide via dry-powder inhaler
Number of subjects: 945

Group type: COMPARATOR
Intervention: Triamcinolone acetonide via pressurized metered-dose inhaler
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 945

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 945
Study: 11318886

Group type: EXPERIMENTAL
Intervention: Isometheptene mucate, dichloralphenazone with acetaminophen
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Sumatriptan succinate
Number of subjects: 137
Study: 9389263

Group type: EXPERIMENTAL
Intervention: Pulse oximeter lower alarm limit set at 90% (group 90)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Pulse oximeter lower alarm limit set at 85% (group 85)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Pulse oximeter lower alarm limit set at 90% with a theoretical delay of 15 s
Number of subjects: 647
Study: 7943128

Group type: EXPERIMENTAL
Intervention: Patching of the eyes from birth to a gestational age of 35 weeks
Number of subjects: 127

Group type: COMPARATOR
Intervention: Cycled lighting conditions (reduced light level during the night)
Number of subjects: 127
Study: 3794875

Group type: EXPERIMENTAL
Intervention: GH plus Cyproheptadine (Cp) 0.25 to 0.4 mg/kg/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: GH alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GH plus Cyproheptadine (Cp)
Number of subjects: 6
Study: 30447891

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 524 mg administered 30 min before DMF
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo administered 30 min before DMF
Number of subjects: 175
Study: 27753427

Group type: EXPERIMENTAL
Intervention: Video chat monitoring for dietary adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video chat monitoring for pill-taking adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey results from study 2
Number of subjects: 0
Study: 26516614

Group type: EXPERIMENTAL
Intervention: l-dopa (Levodopa) administered preoperatively
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: cZi-DBS (deep brain stimulation in caudal zona incerta)
Number of subjects: 11
Study: 23442368

Group type: EXPERIMENTAL
Intervention: $500 electricity voucher paid into the electricity account of older people with COPD (early intervention group)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: $500 electricity voucher paid into the electricity account of older people with COPD (late intervention group)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group (late intervention)
Number of subjects: 522
Study: 20178677

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive-behavior therapy (TF-CBT) or eye movement desensitization and reprocessing (EMDR)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Outreach and screening
Number of subjects: 910
Study: 18808489

Group type: EXPERIMENTAL
Intervention: Intense intervention (n = 54)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Less-intense intervention (n = 58)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (n = 64)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Intense intervention
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Less-intense intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study: 16015461

Group type: EXPERIMENTAL
Intervention: Agreeable behaviour (communal behaviour manipulation)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Quarrelsome behaviour (communal behaviour manipulation)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Quarrelsome behaviour (low communal trait)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Low communal men
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: High communal women
Number of subjects: 66
Study: 12548209

Group type: EXPERIMENTAL
Intervention: Gentamicin 5 mg/kg and clindamycin phosphate 2700 mg administered as a single‐daily dose
Number of subjects: 110

Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg and clindamycin phosphate 900 mg administered every 8 hours
Number of subjects: 110
Study: 10368355

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 29
Study: 8902446

Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg) administered orally, daily for 3-6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (37 men with significant antisperm antibodies)
Number of subjects: 40
Study: 2050169

Group type: EXPERIMENTAL
Intervention: Imipramine + alcohol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Amitriptyline + alcohol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 7

Group type: COMPARATOR
Intervention: Amitriptyline alone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both antidepressants (amitriptyline and imipramine)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Digit symbol substitution test
Number of subjects: 7
Study: 6364591

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) ointment (200 mg applied three times a day for 3 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (applied three times a day for 3 weeks)
Number of subjects: 12
Study: 31345267

Group type: EXPERIMENTAL
Intervention: Combination of durvalumab (1500 mg IV every 4 weeks), olaparib (300 mg twice daily), and cediranib (20 mg, 5 days on/2 days off)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of durvalumab, olaparib, and cediranib
Number of subjects: 9
Study: 29473942

Group type: EXPERIMENTAL
Intervention: Graphical instructions
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standardized instructions
Number of subjects: 92
Study: 26402148

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 23979220

Group type: EXPERIMENTAL
Intervention: Vinegar in palatable drinks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vinegar in unpalatable drinks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orosensory stimulation with vinegar (taste only without ingestion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-vinegar control
Number of subjects: 30
Study: 22201663

Group type: EXPERIMENTAL
Intervention: P6 acupressure plus nurse-provided counseling
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nurse-provided counseling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (placebo on SI3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: P6 acupressure only
Number of subjects: 120
Study: 20117624

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 72

Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 72
Study: 17038536

Group type: EXPERIMENTAL
Intervention: Unrelated cord blood transplantation (CBT)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Bone marrow transplant (BMT) or peripheral blood stem-cell transplant (PBSCT)
Number of subjects: 171
Study: 14994322

Group type: EXPERIMENTAL
Intervention: Quetiapine (mean daily dose 439.5 mg, range 150-750 mg)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Quetiapine (mean daily dose 438.5 mg, range 150-750 mg)
Number of subjects: 258
Study: 11339781

Group type: EXPERIMENTAL
Intervention: 15 ml of 2% mepivacaine via an epidural catheter inserted cephaladly (Group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 5 ml of 2% mepivacaine directly in the epidural needle directed caudally and 10 ml of 2% mepivacaine via the epidural catheter inserted cephaladly (Group B)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 46
Study: 9731851

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1200 mg elemental calcium per day)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study: 7520105

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 545
Study: 2662803

Group type: EXPERIMENTAL
Intervention: Epidural diamorphine 5 mg with bupivacaine 0.25% 10 ml
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 10 ml
Number of subjects: 50
Study: 1200020

Group type: EXPERIMENTAL
Intervention: Endurance training exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low intensity activities (control group)
Number of subjects: 0
Study: 31506246

Group type: EXPERIMENTAL
Intervention: Water-walking (WW)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Land-walking (LW)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 72
Study: 30195244

Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grilled fish (100 g per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (fish oil and fish meal)
Number of subjects: 0
Study: 28712537

Group type: EXPERIMENTAL
Intervention: Bilateral, subretinal injection of 1·5×10^11 vector genomes of voretigene neparvovec in 0·3 mL total volume
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bilateral, subretinal injection of voretigene neparvovec
Number of subjects: 31
Study: 26720026

Group type: EXPERIMENTAL
Intervention: Opiates (n=150)
Number of subjects: 320

Group type: COMPARATOR
Intervention: NSAIDs (n=144)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: 12F chest tube (n=54)
Number of subjects: 320

Group type: COMPARATOR
Intervention: 24F chest tube (n=56)
Number of subjects: 320
Study: 24821885

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (1,400 mg)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (375 mg/m2, 625 mg/m2, or 800 mg/m2)
Number of subjects: 278
Study: 22975039

Group type: EXPERIMENTAL
Intervention: Extracorporeal high-intensity focused ultrasound (HIFU)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 34

Group type: COMPARATOR
Intervention: SVL group (splenic vein ligation)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SVL + HIFU group
Number of subjects: 34
Study: 19182179

Group type: EXPERIMENTAL
Intervention: Risperidone 1.5-6.0 mg/day (regimen A)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Risperidone 0.15-0.6 mg/day (regimen B)
Number of subjects: 257
Study: 17518101

Group type: EXPERIMENTAL
Intervention: Accent on subject
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitch accents within a potential antecedent VP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antecedents containing a focused constituent
Number of subjects: 0
Study: 15615503

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0
Study: 11450689

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 11
Study: 9808278

Group type: EXPERIMENTAL
Intervention: Sympathetic skin response (SSR) in ALS patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Plantar SSR in ALS patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 31
Study: 8541533

Group type: EXPERIMENTAL
Intervention: 1,000 U rHuEpo daily subcutaneously for 8 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 2,000 U rHuEpo daily subcutaneously for 8 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 5,000 U rHuEpo daily subcutaneously for 8 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 10,000 U rHuEpo daily subcutaneously for 8 weeks
Number of subjects: 146

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 146
Study: 2136809

Group type: EXPERIMENTAL
Intervention: 10 mg toremifene
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 20 mg toremifene
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 40 mg toremifene
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 60 mg toremifene
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 200 mg toremifene
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 400 mg toremifene
Number of subjects: 70
Study: 678886

Group type: EXPERIMENTAL
Intervention: Referral to a dietitian
Number of subjects: 49

Group type: COMPARATOR
Intervention: Diet sheet
Number of subjects: 49

Group type: COMPARATOR
Intervention: Doctor's advice to reduce weight
Number of subjects: 49
Study: 31770513

Group type: EXPERIMENTAL
Intervention: CsA CE high-dose (0.1% eye drops, 4 times daily)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: CsA CE low-dose (0.1% eye drops, twice daily + vehicle twice daily)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 142
Study: 31721907

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 28294488

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride 0.5 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study: 26363701

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) plus standard care (medication and contact with the local clinical team)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 50
Study: 24548978

Group type: EXPERIMENTAL
Intervention: Capsule formulation of lenvatinib (10 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-fat meal with capsule formulation of lenvatinib (10 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tablet formulation of lenvatinib (10 mg)
Number of subjects: 36
Study: 22989893

Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Surveillance per AACE/AAES guidelines
Number of subjects: 3

Group type: COMPARATOR
Intervention: No follow-up (sign-off)
Number of subjects: 3
Study: 19876883

Group type: EXPERIMENTAL
Intervention: Gait re‐education programme and bed exercises (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gait re‐education programme without bed exercises (Group B)
Number of subjects: 60
Study: 17548662

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 8369

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8369
Study: 15042464

Group type: EXPERIMENTAL
Intervention: Oxygen-enhanced MRI using dynamically acquired T1 parameter maps
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard pulmonary function test (PFT)
Number of subjects: 8
Study: 11583482

Group type: EXPERIMENTAL
Intervention: Tegaserod (6 mg bid) with digoxin (1 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tegaserod (6 mg bid)
Number of subjects: 12
Study: 9851574

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163